Literature DB >> 19917747

Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.

Elizabeth C Reuman1, Michael H Bachmann, Vici Varghese, W Jeffrey Fessel, Robert W Shafer.   

Abstract

We created an HIV-1 cloning vector, pNL4.3DeltaIN, to generate recombinant infectious molecular clones for analysis of patient-derived HIV-1 integrase coding regions. Using this vector, we constructed a panel of clinically derived viruses with the canonical patterns of raltegravir resistance mutations and submitted the panel to the NIH AIDS Research and Reference Reagent Program. Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clinically relevant raltegravir-resistant variants.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19917747      PMCID： PMC2812164          DOI： 10.1128/AAC.01345-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.

Authors:  Signe Fransen; Soumi Gupta; Arne Frantzell; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

2.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

3.  The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Authors:  Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark R Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

4.  Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.

Authors:  Masanori Kobayashi; Koichiro Nakahara; Takahiro Seki; Shigeru Miki; Shinobu Kawauchi; Akemi Suyama; Chiaki Wakasa-Morimoto; Makoto Kodama; Takeshi Endoh; Eiichi Oosugi; Yoshihiro Matsushita; Hitoshi Murai; Toshio Fujishita; Tomokazu Yoshinaga; Edward Garvey; Scott Foster; Mark Underwood; Brian Johns; Akihiko Sato; Tamio Fujiwara
Journal:  Antiviral Res       Date:  2008-07-14       Impact factor: 5.970

5.  Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.

Authors:  Signe Fransen; Soumi Gupta; Robert Danovich; Daria Hazuda; Michael Miller; Marc Witmer; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

6.  Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

Authors:  Isabelle Malet; Olivier Delelis; Cathia Soulie; Marc Wirden; Luba Tchertanov; Philippe Mottaz; Gilles Peytavin; Christine Katlama; Jean-François Mouscadet; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  J Antimicrob Chemother       Date:  2009-02-16       Impact factor: 5.790

7.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors:  Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  Lancet       Date:  2009-08-03       Impact factor: 79.321

8.  Raltegravir with optimized background therapy for resistant HIV-1 infection.

Authors:  Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Authors:  David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.

Authors:  Soo-Yon Rhee; Tommy F Liu; Mark Kiuchi; Rafael Zioni; Robert J Gifford; Susan P Holmes; Robert W Shafer
Journal:  Retrovirology       Date:  2008-08-07       Impact factor: 4.602
View more
  18 in total

1.  The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.

Authors:  E Herrera-Carrillo; B Berkhout
Journal:  Gene Ther       Date:  2015-02-26       Impact factor: 5.250

2.  Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.

Authors:  Francesco Saladini; Alessia Giannini; Adele Boccuto; Ilaria Vicenti; Maurizio Zazzi
Journal:  J Clin Lab Anal       Date:  2017-03-17       Impact factor: 2.352

3.  A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

Authors:  Ighovwerha Ofotokun; Anandi N Sheth; Sara E Sanford; Kirk A Easley; Neeta Shenvi; Kelly White; Molly E Eaton; Carlos Del Rio; Jeffrey L Lennox
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

4.  SYBR Green II Dye-Based Real-Time Assay for Measuring Inhibitor Activity Against HIV-1 Reverse Transcriptase.

Authors:  Chakradhar Kokkula; Navaneethan Palanisamy; Malin Ericstam; Johan Lennerstrand
Journal:  Mol Biotechnol       Date:  2016-10       Impact factor: 2.695

5.  Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Dmitry S Belov; Pavel O Markov; Alexander V Kurkin; Andrea Altieri; Asim K Debnath
Journal:  J Med Chem       Date:  2020-02-17       Impact factor: 7.446

6.  GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1.

Authors:  Sharon L Karmon; Hiroshi Mohri; William Spreen; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2015-03-01       Impact factor: 3.731

7.  Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors.

Authors:  Michelli F Oliveira; Dulce B Ramalho; Celina M Abreu; Adolfo Vubil; Nédio Mabunda; Nalia Ismael; Cidia Francisco; Ilesh V Jani; Amilcar Tanuri
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

8.  A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.

Authors:  Maurice O Okello; Sanjay Mishra; Malik Nishonov; Marie K Mankowski; Julie D Russell; Jiayi Wei; Priscilla A Hogan; Roger G Ptak; Vasu Nair
Journal:  Antiviral Res       Date:  2013-04-18       Impact factor: 5.970

9.  3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.

Authors:  Bulan Wu; Jing Tang; Daniel J Wilson; Andrew D Huber; Mary C Casey; Juan Ji; Jayakanth Kankanala; Jiashu Xie; Stefan G Sarafianos; Zhengqiang Wang
Journal:  J Med Chem       Date:  2016-06-17       Impact factor: 7.446

10.  Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Evgeny A Spiridonov; Dmitry S Belov; Andrea Altieri; Alexander V Kurkin; Asim K Debnath
Journal:  Bioorg Med Chem       Date:  2021-01-08       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.